BHCM
ASMB icon

Brevan Howard Capital Management’s Assembly Biosciences ASMB Stock Holding History

Brevan Howard Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
7,765
-3,347
-30% -$91.1K ﹤0.01% 1878
2026
Q1 		$308K Buy
+11,112
New +$317K ﹤0.01% 1597

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Brevan Howard Capital Management's ASMB Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Assembly Biosciences (ASMB) stake by 30% in Q2 2026, selling an estimated $91.1K and leaving 7,765 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

Brevan Howard Capital Management first reported a position in ASMB in Q1 2026 and has held it in 2 quarters since. The position peaked at $308K in Q1 2026. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Brevan Howard Capital Management held 7,765 shares of Assembly Biosciences worth $213K as of Q2 2026.
  • Brevan Howard Capital Management sold 3,347 Assembly Biosciences shares in Q2 2026, an estimated $91.1K.
  • Assembly Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1878 holding.
  • Brevan Howard Capital Management first reported a position in Assembly Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Assembly Biosciences position peaked at $308K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.